Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 17/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096257 | 0.88 | POLB (0.67) | POLBNR1H4ALDH1A1GAA | |
| SCHEMBL2003480 | 0.87 | NR1H4 (0.45) | NR1H4 | |
| SCHEMBL19699375 | 0.86 | NR1H4 (0.47) | NR1H4 | |
| SCHEMBL22772582 | 0.85 | NR1H4 (0.50) | POLBNR1H4ALDH1A1GAA | |
| SCHEMBL2003343 | 0.84 | NR1H4 (0.48) | NR1H4 | |
| SCHEMBL1999960 | 0.82 | NR1H4 (0.42) | NR1H4 | |
| SCHEMBL22790236 | 0.81 | POLB (0.58) | POLBNR1H4ALDH1A1GAA | |
| SCHEMBL28596013 | 0.81 | POLB (0.49) | POLBNR1H4ALDH1A1GAA | |
| SCHEMBL22790342 | 0.80 | POLB (0.57) | POLBNR1H4ALDH1A1GAA | |
| SCHEMBL2003625 | 0.80 | NR1H4 (0.44) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111630051-B | Olefin spiro compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-3704112-B1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3704112-B1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-29 | — | — | US | disclosed |
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210179599-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210179599-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3704112-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| CN-111630051-A | Spirocyclic compounds of alkenes as farnesoid X receptor modulators | 百时美施贵宝公司 | 2020-09-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | NR1H2, NR1H4, NR1H3 | POLB 4732/4885NR1H4 2/4885ALDH1A1 1437/4885 |
| US-20210179599-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H2, NR1H4, NR1H3 | POLB 4732/4885NR1H4 2/4885ALDH1A1 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.